Logo

Public Feeds

Public speeches should be public

Politicians, athletes, journalists, NGOs, companies... They all use corporation-owned social networks to communicate with us. Citizens shouldn't have to hand over their data to companies to read content published by public entities. Public Feeds changes that by making posts of popular accounts freely available. Read more.

Filana Therapeutics

Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc., formerly Pain Therapeutics Inc.) is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam (formerly known as PTI-125 and sumifilam) as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. More on Wikipedia